Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Treating Fragile X Syndrome, a Cause of Intellectual Disability, and Huntington’s Disease with Crispr cas9

Treating Fragile X Syndrome, a Cause of Intellectual Disability, and Huntington’s Disease with Crispr cas9

Considered one of the century’s most important discoveries, crispr cas9 technology brings groundbreaking developments in treating diseases every day. Let us examine the latest advances in CRISPR/CAS9.

1. An effective treatment against Huntington’s disease developed with Crispr

Huntington’s disease results from mutations in the huntingtin gene. Repeated CAG sequences prevent the gene from functioning properly. Accumulation of huntingtin protein with high polyglutamine content in brain cells damages and destroys neurons. This disease is inherited from either parent (autosomal dominant). The first symptoms of this neurodegenerative disease, for which no treatment has yet been found, appear at ages 35-44, by which time carriers have often already had children and passed on the mutated huntingtin gene. The disease shortens life by at least 20 years and on average around 35 years.

Researchers precisely removed repeated CAG sequences in the HTT gene using the crispr cas9 system. The study used cells from Huntington’s patients. This newly developed method was found highly reliable in laboratory studies. Clinical trials are planned soon.

2. Treating fragile X syndrome, the leading cause of intellectual disability in males, with Crispr

Fragile X syndrome results from a mutation in the FMR1 gene on the X chromosome. Among every 3600 boys born, 1 has fragile X syndrome. Affected individuals show autism-like problems and hyperactivity, characteristic facial features (a long face and large ears), muscle hypotonia and enlarged testicles. In the FMR1 gene, a mutation means the protein encoded by the FMR1 gene cannot be produced. Deficiency of this protein in brain development causes excessive neuronal stimulation and the disease to develop. There is currently no treatment for fragile X syndrome.

Recently, studies have focused on using Crispr particularly for neurological diseases. For the first time, Whitehead Institute researchers used Crispr to make the damaged gene causing fragile X syndrome healthy . The research was published in February 2018 in Cell . In the study, methylation molecules in repeated CGG sequences of the FMR1 gene were removed using crispr cas9 .

According to the study results

  • Using Crispr cas9 to remove methylation in specific regions of the FMR1 gene reactivated the FMR1 gene.
  • When neurons made healthy through the FMR1 gene were transplanted into a mouse brain, they maintained their healthy structure.

This study shows that fragile X syndrome could be treated using Crispr. It is important to emphasize that this is still a treatment tested in the laboratory. It will be used clinically after human trials evaluate its safety and effectiveness.

- ALL OUR CRISPR ARTICLES - 

Sources

1. X. Shawn Liu ve ark.
Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene.
Cell Şubat 2018.

2. Magdalena Dabrowska ve ark.
Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases.
Front. Neurosci., Şubat 2018

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Treating Fragile X Syndrome, a Cause of Intellectual Disability, and Huntington’s Disease with Crispr cas9

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy